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Abstract 
Background: The effect of CD4 count on malaria incidence in HIV infected adults on antiretroviral therapy (ART) was 
assessed in the context of a randomized controlled trial on the effect of stopping cotrimoxazole (CTX).
Methods: This study presents a sub-analysis of the COSTOP trial (ISRCTN44723643) which was carried out among 
HIV-infected Ugandan adults stable on ART with CD4 counts ≥250 cells/µl. Participants were randomized (1:1) to 
continue CTX or stop CTX and receive matching placebo, and were followed up for a minimum of 1 year (median 
2.5 years). CD4 counts were measured at baseline, 3 months and then every 6 months. Clinical malaria was defined 
as fever and a positive blood slide. First, the relationship between current CD4 count during follow-up and malaria 
among participants on placebo was examined; using random effects Poisson regression to account for repeated epi-
sodes. Second, the effect of CD4 count at enrolment, CD4 count at ART initiation, and CD4 count during follow-up on 
malaria, was assessed within each trial arm; to examine whether the effect of CD4 count differed by CTX use.
Results: 2180 participants were enrolled into the COSTOP trial. The incidence of clinical malaria was approximately 
four episodes/100 person years in the CTX arm and 14 episodes/100 person years in the placebo arm. There was no 
evidence of an association of current CD4 and clinical malaria incidence (P = 0.56), or parasitaemia levels (P = 0.24), 
in the placebo arm. Malaria incidence did not differ by CD4 count at ART initiation, enrolment or during follow up, 
irrespective of CTX use. When compared with participants in the lowest CD4 stratum, rate ratios within each trial arm 
were all close to 1, and P values were all above P = 0.30.
Conclusions: The immune status of HIV infected participants who are stable on ART as measured by CD4 count 
was not associated with malaria incidence and did not modify the effect of stopping CTX on malaria. The decision of 
whether to stop or continue CTX prophylaxis for malaria in HIV infected individuals who are stable on ART should not 
be based on CD4 counts alone.
COSTOP trial registration number ISRCTN44723643
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Background
In many parts of sub-Saharan Africa, both malaria 
and HIV infection are highly endemic. HIV infection 
enhances malaria acquisition and severity; similarly 
malaria enhances HIV viral replication [1–5]. The effect 
of HIV infection on malaria incidence seems to be a con-
sequence of the immune suppression that is a character-
istic of HIV infection [6]. In clinical practice, CD4 cell 
counts are used to measure the degree of HIV-induced 
immune suppression which guides decisions on antiret-
roviral therapy (ART) and the need for prophylaxis 
against opportunistic infections [7, 8].
Decreased CD4 counts have been associated with higher 
risk of acquiring malaria. In a study in rural Uganda, HIV 
infected ART-naïve adults with CD4 counts  <200  cells/
µl had a significantly higher risk of clinical malaria than 
those with CD4 counts ≥500 [9]. A study in HIV infected 
ART-naïve adults in urban Entebbe, Uganda, found that the 
incidence of clinical malaria increased from 57/1000  per-
son years (pyrs) among those with CD4 counts  ≥500–
140/1000 person years in those with CD4 <200 [10]. Both 
studies were done in the 1990s, before ART or cotrimoxa-
zole (CTX) prophylaxis were routinely available in Uganda.
CTX is beneficial to HIV infected individuals as a proph-
ylaxis against malaria and bacterial infections [11–13], 
even when individuals are on ART [14–16], and is recom-
mended for routine use in areas where malaria is highly 
prevalent [8]. Once HIV viral replication is suppressed by 
ART, CD4 counts increase over time [17, 18]. Consequently 
it may be expected that the risk of malaria will decrease as 
individuals’ CD4 counts increase on ART. However, it is 
unclear whether the risk of malaria continues to decrease 
after the immune system has sufficiently recovered on ART, 
or whether there is a CD4 threshold after which malaria 
incidence stabilizes. It is also unclear whether decreased 
CD4 counts would be associated with an increased risk of 
malaria in individuals on CTX prophylaxis.
To address these research questions, we conducted a 
planned sub-group analysis to examine the relationship 
of CD4 count with malaria in the recently completed 
COSTOP trial in Uganda [19–21]. COSTOP was a rand-
omized, placebo-controlled, non-inferiority trial assess-
ing the efficacy and safety of stopping CTX prophylaxis 
among HIV positive adults who were stable on ART. The 
trial found that malaria incidence was higher among those 
who were randomized to stop prophylactic CTX [21]. 
Data from this trial were used to investigate the effect of 
CD4 count on the incidence of malaria, and whether the 
effect of CD4 count on malaria differed by CTX use.
Aim
The study aimed to determine among HIV infected adults 
on ART with CD4 counts ≥250 cells/µl:
i. The effect of CD4 count on malaria incidence
ii. Whether this effect differs in the presence and 
absence of CTX medication
Methods
This study used data gathered during the COSTOP 
trial conducted from 2011 to 2014 in Uganda 
(ISRCTN44723643). Trial methods have been described 
previously [19, 21]. Briefly, COSTOP was a randomized, 
double-blind, placebo controlled non-inferiority trial to 
determine whether long-term prophylaxis with CTX can 
be safely discontinued among HIV infected adults on 
ART with sustained immune competence (defined as a 
confirmed CD4 counts of ≥250 cells/µl). Individuals were 
eligible for enrolment if they were HIV-infected; aged 
18 years or older; clinically asymptomatic; had been tak-
ing CTX and ART for at least 6 months; and had two CD4 
counts (not more than 6 months apart) ≥250 cells/µl, the 
most recent no more than 4  weeks prior to enrolment. 
Exclusion criteria included pregnancy, grade 3 or 4 anae-
mia, neutropaenia or thrombocytopaenia. Participants 
were randomized to receive either active CTX (960 mg) 
or matching placebo once daily after stopping their reg-
ular CTX medication. Randomization was stratified by 
enrolment site (Entebbe or Masaka, both located in SW 
Uganda) and CD4 count (≥250–499 and ≥500 cells/µl).
Study procedures
Informed consent for study procedures was obtained at 
screening and enrolment.
At screening, data were documented on; disease his-
tory, duration of prior ART and CTX medication, and 
CD4 count at time of ART initiation. At enrollment, data 
were documented on socio-demographic characteristics 
and each participant was provided with an insecticide-
treated bed net (ITN) and educated about the importance 
of using it. Participants were seen at scheduled follow-up 
visits every month for the first 3 months and 3-monthly 
thereafter, and were followed for 12 months to 3.5 years, 
depending on date of enrolment. At these visits, partici-
pants were asked about their health, symptoms sugges-
tive of malaria, adherence to medication and bed net 
use. Blood samples were drawn; at enrollment, monthly 
for 3  months and 3  monthly thereafter for a malaria 
slide; at 3  months, 6  months and 6  monthly thereafter 
for CD4 count; and 3  monthly for the full blood count. 
Participants were asked to attend the study clinic at any 
time they felt unwell; if malaria was suspected, based on 
a history of malaria associated symptoms (fever, head-
ache, chills and rigors, joint aches, muscles aches, vom-
iting or diarrhea), a blood slide and other tests deemed 
necessary were done. Participants who reported having 
been treated for malaria elsewhere (for example during a 
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journey) were asked to present documentary evidence of 
diagnoses and test results.
Laboratory methods
A sample of blood was taken either from the fingertip 
using a lancet or from a peripheral vein using a syringe, 
and used to prepare thick and thin films on a glass slide. 
The specimens were processed using Leishman’s stain 
and examined by microscopy. Thick film specimens were 
used to record the number of parasites per 200 white 
blood cells and thin films to identify the plasmodium 
species. Venous blood samples were taken for CD4 cell 
counts and measured using a FACS-count system (Bec-
ton–Dickinson San Jose) at the MRC/UVRI laboratories 
in Entebbe and Masaka.
Statistical analysis
Analyses were carried out using Stata 13. Clinical malaria 
was defined as presence or history (during the previous 
2  weeks) of fever and microscopically confirmed malaria 
parasites. Severe malaria (based on WHO guidelines) [21, 
22] was diagnosed if a participant had Plasmodium fal-
ciparum asexual parasitaemia, no other obvious cause of 
symptoms and met any of the following criteria: convul-
sions, loss of consciousness, hypotension (systolic blood 
pressure <70 mmHg), admission to hospital due to malaria, 
laboratory evidence of liver or kidney damage, severe nor-
mocytic anaemia (haemoglobin <50 g/dl, PCV < 15 %), or 
hyper parasitaemia on blood slide (>5 % or 250,000/µl).
The CD4 count at enrolment was calculated from the 
mean of the two most recent pre-enrolment (screening) 
CD4 counts. Person years at risk were calculated from 
enrolment until the date last seen or end of trial. After 
each malaria episode, participants were considered to be 
not at risk for another episode until the episode resolved, 
or for 28 days, if a resolution date was not available. Fol-
low-up data were organized into intervals corresponding 
with the visit schedule. For time-varying variables during 
follow-up (e.g. CD4 count at malaria infection, BMI), the 
most recent value measured at the start of each interval 
was used. CD4 count values were carried forward for the 
visits where CD4 counts were not done, until the next 
recorded CD4 count.
First, the effect of current (time of infection) CD4 
count on clinical malaria incidence during follow up 
was assessed; using random effects Poisson regression 
to account for the clustering of multiple episodes within 
the same participant. Since the incidence of malaria in 
the COSTOP trial had previously been shown to be sig-
nificantly lower in the CTX arm (21), this analysis was 
restricted to participants in the placebo arm in order to 
examine the effect of CD4 counts in the absence of the 
anti-malarial effects of CTX. The effect of CD4 adjusted 
for baseline covariates that were considered as potential 
confounders a priori (enrolment site, age, sex, socioeco-
nomic status (SES) and baseline CD4 count) was exam-
ined, and then including time-varying variables (time 
since enrolment, current BMI). SES was measured by 
combining baseline data from all trial participants on 
housing construction and ownership of household items 
into an asset index score using principal component 
analysis [23]. In order to allow for non-linear effects, 
CD4 at infection, baseline CD4 and age were modelled 
using restricted cubic splines with 4 knots; this approach 
provides a flexible way to model the shape of the rela-
tionship of a continuous variable with the outcome [24].
Among placebo participants with clinical malaria, the 
effect of CD4 count at infection on parasitaemia during 
each malaria episode as the outcome was assessed, using 
random effects linear regression; parasitaemia levels were 
log transformed for analysis. The analysis was adjusted 
for baseline and time-varying potential confounders as 
described above. In addition, CD4 count at infection was 
assessed for an effect on severe malaria; since there were 
only 15 episodes of severe malaria (13 placebo, two on 
CTX) [21], no attempt was made to adjust for potential 
confounders.
Secondly, the effect of CD4 count at baseline, CD4 
count at ART initiation, or CD4 count at infection on 
clinical malaria was assessed by treatment arm (CTX 
or placebo), using random effects Poisson regression. 
Regression models contained fixed effects for CD4 count 
group, treatment arm, enrolment site and year since 
enrolment, and an interaction term between CD4 count 
group and treatment arm.
Results
2180 participants were enrolled into the COSTOP trial, 
1002 (46 %) at the Entebbe site, and 1091 (50 %) were allo-
cated to placebo (stopping CTX). Baseline characteristics 
were well balanced between trial arms (Additional file 1). 
Mean age at enrolment was 41 years and 74 % were female. 
The median (IQR) CD4 count at ART initiation was 155 
(89–199) and 159 (83–214) for Entebbe and Masaka, 
respectively, and the median (IQR) CD4 count at enrol-
ment was 446 (361–600) and 519 (397–655), respectively. 
At the Entebbe site, 56 (5.7 %) participants were on a pro-
tease inhibitor (PI)-containing regimen compared to 30 
(2.6 %) at Masaka. 239 (24 %) participants in Entebbe and 
220 (19 %) in Masaka site had been on ART for <2 years.
Effect of CD4 on malaria
Among participants in the placebo arm, overall clinical 
malaria incidence was 14.1/100  person years (95  % CI 
12.5–15.8). There was no evidence of an effect of CD4 
count at infection on clinical malaria (P = 0.56; Table 1; 
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Fig. 1). Furthermore, there was no evidence that parasi-
taemia levels differed by CD4 count at infection (P = 0.24 
from random effects linear regression model; Fig. 2).
There were 15 cases of severe malaria (13 placebo, 2 
CTX). Severe malaria rates decreased with increasing 
CD4 counts among participants with CD4  <400, then 
Table 1 Association of CD4 count (at infection) with malaria in the placebo arm
a Rates and rate ratios estimated from random effects Poisson regression
b Adjusted for enrolment site, age at enrolment, sex, SES and baseline CD4 count
c Adjusted for all covariates in footnote b, and time since enrolment, current BMI and bednet use
d Continuous covariates (CD4 count and age) were modelled by restricted cubic splines with 4 knots. Rates are estimated at the median value in each range; the 
median value in the lowest range is used as the reference to estimate the rate ratios. P value is for overall association with covariate from likelihood ratio test
Clinical malaria
Median 
value
Rate/100 person years 
(95 % CI)a
Crude rate ratio 
(95 % CI)a
Adjusted rate ratio 
(95 % CI)a,b
Adjusted rate ratio 
(95 % CI)a,c
CD4 count at infectiond P = 0.60 P = 0.81 P = 0.56
 <300 262 14.6 (11.2–19.0) 1 1 1
 300–399 355 13.4 (11.0–16.3) 0.9 (0.7–1.1) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
 400–499 448 13.1 (11.1–15.5) 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.9 (0.6–1.3)
 500–599 547 13.5 (11.5–15.9) 0.9 (0.7–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.4)
 600–699 644 14.2 (11.7–17.1) 1.0 (0.7–1.4) 0.9 (0.6–1.5) 1.0 (0.6–1.6)
 ≥700 836 15.5 (12.7–19.0) 1.1 (0.8–1.5) 1.0 (0.6–1.7) 1.2 (0.7–1.9)
Baseline factors
 Site P < 0.001 P < 0.001 P = 0.002
  Entebbe 10.6 (8.8–12.8) 1 1 1
  Masaka 17.2 (14.9–19.9) 1.6 (1.3–2.1) 1.5 (1.2–1.9) 1.5 (1.1–1.9)
 Age (years)d P = 0.07 P = 0.04 P = 0.04
  <35 31 12.4 (10.0–15.2) 1 1 1
  35–44 39 15.1 (12.8–17.9) 1.2 (1.0–1.5) 1.2 (1.0–1.5) 1.2 (1.0–1.5)
  ≥45 50 14.0 (11.5–17.1) 1.1 (0.8–1.5) 1.1 (0.8–1.4) 1.1 (0.8–1.5)
 Sex P = 0.83 P = 0.46 P = 0.63
  Male 14.4 (11.4–18.1) 1 1 1
  Female 13.9 (12.2–16.0) 1.0 (0.7–1.3) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
 SES P < 0.001 P = 0.002 P = 0.003
  Low 16.1 (13.6–19.0) 1.8 (1.3–2.4) 1.7 (1.3–2.4) 1.7 (1.2–2.3)
  Middle 15.7 (12.8–19.1) 1.7 (1.2–2.4) 1.6 (1.1–2.2) 1.6 (1.1–2.2)
  High 9.0 (6.9–11.8) 1 1 1
 Baseline CD4 countd P = 0.63 P = 0.88 P = 0.98
  <350 310 13.3 (10.4–16.9) 1 1 1
  350–499 422 13.1 (10.7–16.1) 1.0 (0.7–1.3) 1.0 (0.7–1.3) 1.0 (0.7–1.4)
  ≥500 634 14.7 (12.1–18.0) 1.1 (0.8–1.5) 1.0 (0.8–1.4) 1.0 (0.6–1.5)
Factors during follow-up
 Time since enrolment (years) P < 0.001 P < 0.001
  <1 17.3 (14.8–20.1) 1.9 (1.4–2.6) 1.9 (1.4–2.7)
  1–2 13.1 (10.8–15.7) 1.4 (1.0–2.0) 1.5 (1.0–2.1)
  ≥2 9.0 (6.7–12.1) 1 1
 BMI (kg/m2) P = 0.01 P = 0.02
  <18.5 10.0 (6.9–14.4) 0.6 (0.4–0.9) 0.6 (0.4–0.9)
  18–24.9 15.8 (13.8–18.1) 1 1
  ≥25 11.6 (8.9–15.0) 0.7 (0.5–1.0) 0.8 (0.6–1.0)
 Bed net use P = 0.05 P = 0.14
  ≥90 % of visits 13.2 (11.6–15.1) 1 1
  <90 % of visits 17.5 (13.7–22.3) 1.3 (1.0–1.7) 1.2 (0.9–1.6)
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remained fairly similar in participants with higher CD4 
counts. (P = 0.14; Additional file 2).
Effect of CD4 count on malaria by trial arm
The incidence of malaria did not differ significantly 
between CD4 count strata, neither for CD4 count at 
infection, CD4 count at ART initiation or CD4 count at 
enrolment into the study, and this was irrespective of 
whether participants were in the CTX arm or the pla-
cebo arm of the trial. Although malaria incidence was 
significantly lower in the CTX arm than on placebo [21], 
compared to participants on the lowest CD4 stratum, 
rate ratios were all close to 1 and P values were all above 
P = 0.30 for each of the three CD4 measures and within 
each arm (Table 2).
Discussion
Previous studies in HIV-infected adults have reported 
an increase in malaria incidence with decreasing CD4 
counts [9, 10], but these studies were in individuals who 
were not on ART.
The incidence of clinical malaria in COSTOP trial par-
ticipants was lower in the CTX arm compared to pla-
cebo, and reduced during follow up [21]. This reduction 
over time was primarily driven by reduced incidence 
in the placebo arm while incidence in the CTX arm 
remained fairly constant. One possible explanation is 
that the immune system recovers in individuals on ART 
and is, therefore, able to more effectively control malaria 
infection. In the COSTOP trial, there was evidence of 
continued recovery of the immune system in HIV-
infected participants who are stable on ART as shown 
by an increase in CD4 counts over time, particularly in 
participants on placebo [20]. However, no evidence was 
found of the expected association between CD4 count 
and the incidence of clinical malaria, or degree of para-
sitaemia. This lack of an effect of CD4 count on malaria 
was observed for CD4 count at the time of starting ART 
(considered a measure of the extent of immune damage 
before starting ART), time of randomization (indicat-
ing the immune status at beginning of study) and time 
of malaria episode, in participants who continued CTX 
prophylaxis and in those who stopped. Results from this 
study are consistent with those of a recent unblinded 
trial of CTX discontinuation in adults on ART in Kenya, 
which found that the effect of stopping CTX on malaria 
was similar in participants with CD4 count  ≤600 at 
enrolment and those with CD4  >600 [25]. However, 
there were very few malaria episodes in that trial (34 in 
total), and the authors did not directly examine the rela-
tionship between CD4 count and malaria. One possible 
explanation for these findings is that there is a threshold 
below which CD4 count significantly influences the risk 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Ra
te
 ra
tio
 o
f m
al
ar
ia
200 300 400 500 600 700 800 900 1000
Current CD4 count
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Ra
te
 ra
tio
 o
f m
al
ar
ia
200 300 400 500 600 700 800 900 1000
Current CD4 count
a
b
Fig. 1 Association of malaria incidence rate ratios (and 95 % 
confidence intervals) with CD4 count at time of malaria episode as 
observed during follow up, modelled using restricted cubic splines 
with 4 knots in a random effects Poisson regression model, unad-
justed (a), and adjusted for covariates during baseline and follow up 
(b). A CD4 count of 200 was used as the reference to calculate the 
rate ratios
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Fig. 2 Parasite counts by CD4 count at infection among participants 
in the placebo arm with clinical malaria. The central line represents the 
median; boxes represent 75th and 25th centiles; whiskers represent 
upper and lower adjacent values and dots represent outside values
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of malaria. All participants in the COSTOP trial had a 
CD4 count ≥250 cells/µl at enrolment, and those in the 
Kenya trial had a CD4 count >350. An alternative expla-
nation could be that an improvement of CD4 cell qual-
ity rather than quantity under ART may be important 
for malaria containment [26]. In this study, there was no 
evidence of an effect of CD4 count on severe malaria; 
however, because there were so few cases of severe 
malaria, our power to detect significant associations 
was poor.
Strengths and limitations of the study
This study made use of a well-documented data set from 
a large trial of HIV-infected adults on ART. The large 
sample size and the regular collection of data on expo-
sures (CD4 count), outcomes (clinical malaria and para-
sitaemia) and a variety of potential confounders made 
it possible to investigate the research questions in great 
detail.
This study had some limitations. In spite of the large 
sample size only a small number of severe malaria epi-
sodes occurred which limited the power to detect a 
potential effect of CD4 count. Also, the study was not a 
priori designed to address detailed research questions 
related to malaria, but rather was conducted as a sub-
analysis of data gathered in the context of a randomized 
trial on the effect of stopping CTX. Although some 
potential confounders were adjusted for, residual con-
founding cannot be ruled out as a result of imperfectly 
measured covariates which were adjusted for (e.g. SES) 
or covariates which were not measured. Furthermore, 
viral load, which may be a better indicator of immune 
competence than CD4 count was not measured: it has 
been shown that effective viral suppression reduces the 
incidence of opportunistic infections [27] and a similar 
effect might be expected for clinical malaria. Lastly, it 
was not possible to investigate the immune responses 
to malaria which might have provided insight into why 
CD4 counts had no apparent effect on malaria incidence.
Conclusions
In this study of HIV-infected individuals on ART with 
baseline CD4 counts  ≥250  cells/µl, the incidence of 
clinical malaria and the intensity of parasitaemia among 
Table 2 Effect of trial drug on malaria, by CD4 count at enrolment, ART initiation and at the time of malaria episode
a Marginal means from random effects Poisson regression model with fixed effects for CD4 count stratum, treatment arm and their interaction, and site and year since 
enrolment
b Rate ratio for effect of treatment arm in each CD4 count stratum, adjusted for site and year since enrolment, from random effects Poisson regression model
c P values for overall association of CD4 count with malaria incidence within each treatment arm. P values for interaction between CD4 count and treatment arm: CD4 
count at ART initiation P = 0.87; CD4 count at enrolment P = 0.60; CD4 count at infection P = 0.96
Trial arm Stratum Episodes Person  
years
Rate/100 person  
years (95 % CI)a
Rate ratiob P valuec
CD4 count at ART initiation
 CTX <100 30 698 4.0 (2.8–5.9) 1 0.99
100–249 59 1461 3.9 (3.0–5.1) 1.0 (0.6–1.5)
250+ 10 229 3.9 (2.0–7.4) 1.0 (0.5–2.0)
 Placebo <100 92 709 12.4 (9.8–15.7) 1 0.73
100–249 196 1458 13.4 (11.4–15.7) 1.1 (0.8–1.4)
250+ 36 212 14.7 (10.1–21.5) 1.2 (0.8–1.9)
CD4 count at enrolment
 CTX <350 14 416 3.5 (2.0–5.9) 1 0.51
350–499 32 900 3.4 (2.4–4.8) 1.0 (0.5–1.9)
500+ 57 1234 4.3 (3.3–5.7) 1.3 (0.7–2.3)
 Placebo <350 58 453 13.1 (9.8–17.5) 1 0.98
350–499 117 850 13.6 (11.1–16.7) 1.0 (0.7–1.5)
500+ 175 1211 13.4 (11.3–16.0) 1.0 (0.7–1.4)
CD4 count at infection
 CTX <350 21 4618 4.4 (2.9–6.9) 1 0.52
350–499 30 8811 3.3 (2.3–4.7) 0.7 (0.4–1.3)
500+ 52 1197 4.0 (3.0–5.4) 0.9 (0.5–1.5)
 Placebo <350 60 390 14.6 (11.1–19.2) 1 0.32
350–499 98 807 11.8 (9.5–14.6) 0.8 (0.6–1.1)
500+ 192 1317 14.1 (12.0–16.5) 1.0 (0.7–1.3)
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patients with clinical malaria were not influenced by CD4 
counts at ART initiation, enrollment into the study, or at 
the time of malaria infection. The finding of no associa-
tion between malaria and CD4 count was similar among 
participants randomized to stop prophylactic CTX and 
those who continued CTX. The decision of whether to 
stop or continue CTX prophylaxis for malaria in HIV 
infected patients who are stable on ART should not be 
based on a patient’s CD4 cell count alone.
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